Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals

Официальное название

An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 forInjection in Antiretroviral Therapy-Naive HIV-Infected Individuals

Обзор

An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 for Injection in Antiretroviral Therapy-Naive HIV-Infected Individuals

Подробное описание

The study utilizes a sequential cohort design, with three dosage cohorts (20 mg, 40 mg, 80 mg). The cohorts will be enrolled sequentially from low to high doses, with the next dose group initiating subject screening and enrollment after the last subject in the previous cohort has been enrolled.

The study plans to enroll a total of 30 subjects, with 10 subjects in each cohort. Enrolled subjects will receive LP-98 treatment at doses of 20 mg, 40 mg, or 80 mg according to their assigned cohort. The drug will be administered via subcutaneous injection, with an interval of 14 days between doses, for a total of 4 doses.

The study includes a screening phase (D-28 to D-1), a treatment phase (D1 to D57), and a follow-up phase (D58 to D71). The total duration of participation for each subject is approximately 99 days.

Вмешательства

• Препарат LP-98 20 mg
  The study plans to enroll a total of 30 subjects, with 10 subjects in each cohort. Enrolled subjects will receive LP-98 treatment at doses of 20 mg, 40 mg, or 80 mg according to their assigned cohort. The drug will be administered via subcutaneous injection, with an interval of 14 days between doses, for a total of 4 doses.
• Препарат LP-98 40 mg
  LP-98 40 mg
• Препарат LP-98 80 mg
  LP-98 80 mg

Первичные конечные точки

• Plasma HIV RNA levels (log10 copies/mL) and changes from baseline [Срок оценки: Within 71 days after the first administration.]
• Proportion of subjects with plasma HIV RNA < 50 copies/mL [Срок оценки: Within 71 days after the first administration.]
• Proportion of subjects with plasma HIV RNA < 200 copies/mL [Срок оценки: Within 71 days after the first administration.]
• Absolute CD4+ T lymphocyte count and change from baseline [Срок оценки: Within 71 days after the first administration.]
• CD4+/CD8+ T lymphocyte ratio and change from baseline [Срок оценки: Within 71 days after the first administration.]

Вторичные конечные точки (12)

• Changes from baseline in respiration rate of Vital Signs. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in blood pressure of Vital Signs. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in Blood lactate of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in body temperature of Vital Signs. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in red blood cell count of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in white blood cell count of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in neutrophil count of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in lymphocyte count of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in platelet count of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in hemoglobin of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in PT of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]
• Changes from baseline in INR of Laboratory Examination. [Срок оценки: Within 71 days after the first administration.]

Критерии участия

Критерии включения

• The subject must voluntarily agree to participate in the study and provide informed consent before undergoing any study-related assessments.
• At the time of screening, the subject must be between 18 and 65 years of age (inclusive), either male or female.
• At the time of screening, male subjects must weigh at least 50 kg, and female subjects must weigh at least 45 kg.
• Plasma HIV RNA levels must be ≥1000 copies/mL, and CD4+ T lymphocyte count must be ≥200 cells/μL.
• For Female Subjects: Only non-reproductive females will be included, which includes those who have undergone surgical sterilization (documented hysterectomy or bilateral oophorectomy) at least 6 weeks prior to the screening visit, or those who have been postmenopausal for at least 12 months (confirmed by a follicle-stimulating hormone (FSH) level ≥40 IU/L).
• For Male Subjects with Fertile Female Partners: The subject must agree to use a non-pharmacological contraception method for 14 days prior to dosing, during the study, and for 3 months following the administration of the study drug. Male subjects must not donate sperm during this period.
• The subject must be willing to adhere to the study protocol, including visits, study treatment, laboratory tests, and other study-related procedures and requirements.

Критерии исключения

• Known allergy to the study drug or its excipients, or a history of severe allergic reactions (including any food allergies or drug allergies).
• Has previously received antiviral therapy (ART) or has been vaccinated against HIV.
• A history of severe disease or the presence of other severe chronic conditions.
• A history of mental health disorders or a family history of psychiatric diseases.
• Any of the Following Conditions:

1）Persistent unexplained fever above 38°C within 1 month prior to screening or during the screening phase.

2）Persistent diarrhea (more than 3 bowel movements per day) within 1 month prior to screening or during the screening phase.

3）Severe infections, opportunistic infections, or sepsis within 6 months prior to screening or during the screening phase.

6、Positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab).

7、Abnormal 12-lead electrocardiogram (ECG) findings with clinical significance at screening, such as a male QTcF interval (Fridericia correction formula) > 450 ms, or female QTcF > 470 ms.

8、Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times the upper limit of normal (ULN), or total bilirubin > 1.5 times ULN at screening.

9、Serum creatinine clearance (Ccr) < 60 mL/min at screening (calculated using the Cockcroft-Gault formula).

10、Known or suspected history of drug abuse (including morphine, methamphetamine, ketamine, dimethylthioamphetamine, tetrahydrocannabinolic acid, cocaine), or a positive baseline drug screening test.

11、A history of alcohol abuse within the past year (defined as consuming more than 14 standard units of alcohol per week, where 1 standard unit is 14 g of alcohol, equivalent to 360 mL of 5% beer, 45 mL of 40% liquor, or 120 mL of 12% wine), or inability to comply with the study's alcohol prohibition during the study.

12、Smoking more than 5 cigarettes per day within the last 3 months prior to screening, or inability to comply with the study's smoking prohibition during the study.

13、Receiving any vaccine within 3 months prior to screening, or planning to receive any vaccine during the study.

14、Received any investigational drug treatment or participated in any drug/device trial (excluding in vitro diagnostic devices) within 3 months prior to dosing.

15、Major surgery within 30 days prior to dosing, or planned major surgery during the study.

16、Blood donation or loss of ≥ 400 mL within 3 months prior to screening, or receiving a blood transfusion during this period.

17、Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Нерандомизированное

Модель

Последовательный дизайн

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Tianjin Second People's Hospital — Тяньцзинь

Идентификаторы

NCT: NCT07433387 · KB_LP-98_103

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗